Piogny la Foret, France

François Rougeon


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2005

Loading Chart...
1 patent (USPTO):Explore Patents

Title: François Rougeon: Innovator in Peptide Research

Introduction

François Rougeon is a notable inventor based in Piogny la Foret, France. He has made significant contributions to the field of peptide research, particularly in the development of therapeutic and diagnostic products derived from the submaxillary gland of the rat. His work has implications for both medical diagnosis and treatment.

Latest Patents

François Rougeon holds a patent titled "Peptides and Polypeptides Derived from the Submaxillary Gland of the Rat Corresponding Polyclonal and Monoclonal Antibodies Corresponding Hybridomas and Uses of These Products for Diagnosis for Detection or Therapeutic Purposes." This invention relates to a purified peptide with the formula X-His-Asn-Pro-Y, where X represents a Gln or Pro-Glu residue and Y represents an OH group or a residue of a basic amino acid. The patent also covers corresponding polyclonal and monoclonal antibodies, as well as hybridomas, which are useful for therapeutic, diagnostic, and detection purposes. François Rougeon has 1 patent to his name.

Career Highlights

François Rougeon is affiliated with the prestigious Institute Pasteur, where he conducts his research. His work at this renowned institution has allowed him to explore innovative approaches in peptide science, contributing to advancements in medical research.

Collaborations

François has collaborated with notable colleagues, including Isabelle Rosinski-Chupin and Diana Tronik. These partnerships have enhanced his research efforts and broadened the impact of his work in the scientific community.

Conclusion

François Rougeon is a distinguished inventor whose research in peptide technology has the potential to revolutionize diagnostic and therapeutic practices. His contributions to the field are invaluable and continue to inspire future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…